Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of JT001 (VV116) Compared With Paxlovid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who have a positive SARS-CoV-2 test result.~* Participants who have one or more mild or moderate COVID-19 symptoms, and total symptom score ≥ 2.~* Participants who have one or more of the following requirements: ≤7 days from the first positive test for SARS-COV-2 virus infection to the first dose; ≤5 days from the first onset of COVID-19 symptoms to the first dose; SARS-CoV-2 Ct Value ≤20 within 24 hours prior to the first dose.~* Participants who satisfy one or more than one of the following high risks for progression to severe COVID-19, including death.~* Participants who must agree to adhere to contraception restrictions.~* Participants who understand and agree to comply with planned study procedures.~* Participants or legally authorized representatives can give written informed consent approved by the Ethical Review Board governing the site.~* Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.~Exclusion Criteria:~* Participants who are judged by the investigator as likely to progress to severe/critical COVID-19 prior to randomization.~* Participants who have SpO2≤93% on room air at sea level or PaO2/FiO2≤ 300, or respiratory rate ≥30 per minute.~* Participants who require mechanical ventilation or anticipated impending need for mechanical ventilation.~* Participants who have eye disease.~* Participants who have any of the following conditions when screening: ALT or AST\>1.5 ULN; e GFR \<60 mL/min.~* Participants who have known allergies to any of the components used in the formulation of the interventions.~* Any medical condition, which in the opinion of the Investigator, will compromise the safety of the participant.~* Participants who have received a SARS-CoV-2 monoclonal antibody treatment or prevention, or antiviral treatment (including the investigational treatment).~* Participants who have received convalescent COVID-19 plasma treatment.~* Participant's use of contraindicated drugs in the Package Insert of Nirmatrelvir Tablet/Ritonavir Tablets.~* Participants who have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed.~* Participants who are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.~* Female who is pregnant or breast-feeding or plan to be pregnant within this study period.~* Male whose wife or partner plan to be pregnant within this study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- JT001(VV116) (Type: EXPERIMENTAL): Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
- Paxlovid (Type: ACTIVE_COMPARATOR): Day 1\~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).